您是记者吗？

了解 ALK

如有任何疑问，请直接联系 ALK 总部或任何全球办事处的媒体关系部。

The press releases in this press room contains information that is of general news value for the press, and available for journalists or media with a view to journalistic assessment and preparation before publication.

News

See all
  • Post date
    04/23/2025
    ITULAZAX® tree pollen tablet approved for treatment of children in Europe
    Read more
  • Post date
    04/03/2025
    Grant of share-based long-term incentive instruments to members of the Board of Management and key employees
    Read more
  • Post date
    03/13/2025
    Annual General Meeting in ALK-Abelló A/S held on 13 March 2025
    Read more
  • Post date
    03/07/2025
    ACARIZAX® approved in Canada for treatment of young children
    Read more
  • Post date
    03/04/2025
    Report on transactions with ALK-Abelló A/S B shares and associated securities by managerial staff
    Read more
  • Post date
    02/27/2025
    FDA approves ODACTRA® for the treatment of house dust mite allergy in young children
    Read more
  • Post date
    02/21/2025
    Report on transactions with ALK-Abelló A/S B shares and associated securities by managerial staff
    Read more
  • Post date
    02/19/2025
    Annual General Meeting in ALK-Abelló A/S on 13 March 2025
    Read more
  • Post date
    02/19/2025
    Annual report 2024: ALK delivers 15% sales growth with profits up 65%
    Read more

媒体关系

投资者关系

Per Plotnikof

企业传播、

投资者关系和战略规划

副总裁

电话：+45 2261 2525

电子邮件：PPIDK@alk.net

 

媒体关系

Jeppe Ilkjær

企业传播

媒体关系经理

电话：+45 3050 2014

电子邮件：Jeppe.Ilkjaer@alk.net

公司简介
快速了解过敏症免疫治疗市场中的领导者 ALK 的概况
关键财务数据
阅读 ALK 的最新财务业绩
欢迎记者朋友随时联系 ALK 的媒体关系团队。

图片

查找各种可供下载的图片。
Steen Riisgaard, CEO
下载图片
Production facilities, Hørsholm
下载图片
alk_produktion6_0
Production facilities, Hørsholm
下载图片
alk_produktion3_1
Production facilities, Hørsholm
下载图片
alk_produktion5
Production facilities, Hørsholm
下载图片
Family_website_0
ALK HQ, Hørsholm
下载图片
最近更新: 2016.11.14